ES2918626T3 - Receptor antigénico quimérico. - Google Patents
Receptor antigénico quimérico. Download PDFInfo
- Publication number
- ES2918626T3 ES2918626T3 ES14784368T ES14784368T ES2918626T3 ES 2918626 T3 ES2918626 T3 ES 2918626T3 ES 14784368 T ES14784368 T ES 14784368T ES 14784368 T ES14784368 T ES 14784368T ES 2918626 T3 ES2918626 T3 ES 2918626T3
- Authority
- ES
- Spain
- Prior art keywords
- cell
- car
- cells
- bcma
- april
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 133
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims abstract description 98
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims abstract description 98
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 81
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 55
- 125000006850 spacer group Chemical group 0.000 claims abstract description 47
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 16
- 230000003834 intracellular effect Effects 0.000 claims abstract description 11
- 230000005754 cellular signaling Effects 0.000 claims abstract description 9
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 31
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 31
- 150000007523 nucleic acids Chemical group 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 17
- 239000003446 ligand Substances 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 208000021161 Plasma cell disease Diseases 0.000 claims description 10
- 102000016611 Proteoglycans Human genes 0.000 claims description 9
- 108010067787 Proteoglycans Proteins 0.000 claims description 9
- 208000007452 Plasmacytoma Diseases 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 102000001493 Cyclophilins Human genes 0.000 claims description 4
- 108010068682 Cyclophilins Proteins 0.000 claims description 4
- 206010053869 POEMS syndrome Diseases 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 4
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 3
- 206010002022 amyloidosis Diseases 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims description 3
- 208000025750 heavy chain disease Diseases 0.000 claims description 3
- 201000000564 macroglobulinemia Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 3
- 201000009234 osteosclerotic myeloma Diseases 0.000 claims description 3
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 210000004180 plasmocyte Anatomy 0.000 abstract description 10
- 230000001404 mediated effect Effects 0.000 abstract description 2
- 108010065323 Tumor Necrosis Factor Ligand Superfamily Member 13 Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 81
- 201000000050 myeloid neoplasm Diseases 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 24
- 108010076504 Protein Sorting Signals Proteins 0.000 description 18
- 239000000427 antigen Substances 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 238000003501 co-culture Methods 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 6
- 102000008070 Interferon-gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960003130 interferon gamma Drugs 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 5
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 4
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 208000037914 B-cell disorder Diseases 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 230000029918 bioluminescence Effects 0.000 description 3
- 238000005415 bioluminescence Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000003720 plasmablast Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 108010087967 type I signal peptidase Proteins 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000830600 Homo sapiens Tumor necrosis factor ligand superfamily member 13 Proteins 0.000 description 2
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100024585 Tumor necrosis factor ligand superfamily member 13 Human genes 0.000 description 2
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 2
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 2
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 1
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 101710148099 Blue fluorescence protein Proteins 0.000 description 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101100425947 Mus musculus Tnfrsf13b gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 210000000428 immunological synapse Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1317929.6A GB201317929D0 (en) | 2013-10-10 | 2013-10-10 | Chimeric antigen receptor |
| PCT/GB2014/053058 WO2015052538A1 (en) | 2013-10-10 | 2014-10-10 | Chimeric antigen receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2918626T3 true ES2918626T3 (es) | 2022-07-19 |
Family
ID=49679854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14784368T Active ES2918626T3 (es) | 2013-10-10 | 2014-10-10 | Receptor antigénico quimérico. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10160794B2 (OSRAM) |
| EP (1) | EP3055326B1 (OSRAM) |
| JP (2) | JP6632073B2 (OSRAM) |
| KR (1) | KR20160067177A (OSRAM) |
| CN (1) | CN105658671B (OSRAM) |
| AU (1) | AU2014333564B2 (OSRAM) |
| BR (1) | BR112016007805A2 (OSRAM) |
| CA (1) | CA2926560A1 (OSRAM) |
| CL (1) | CL2016000734A1 (OSRAM) |
| ES (1) | ES2918626T3 (OSRAM) |
| GB (1) | GB201317929D0 (OSRAM) |
| IL (1) | IL244784A0 (OSRAM) |
| MX (1) | MX2016004362A (OSRAM) |
| RU (2) | RU2019102382A (OSRAM) |
| SG (1) | SG11201602414SA (OSRAM) |
| WO (1) | WO2015052538A1 (OSRAM) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| ES2737690T3 (es) | 2014-02-27 | 2020-01-15 | Ucl Business Ltd | Variantes de APRIL |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US11982672B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| JP6698546B2 (ja) * | 2014-04-14 | 2020-05-27 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体 |
| CA2973529A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| SG11201707089WA (en) | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| GB201507111D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| GB201507108D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| HRP20200390T1 (hr) | 2015-08-03 | 2020-06-12 | Engmab Sàrl | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017130223A2 (en) | 2016-01-29 | 2017-08-03 | Virocan Therapeutics Pvt. Ltd. | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof |
| CN109475629A (zh) | 2016-05-20 | 2019-03-15 | 伊莱利利公司 | 用notch和pd-1或pd-l1抑制剂的组合治疗 |
| AU2017276706B2 (en) | 2016-06-07 | 2024-08-15 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| IL266424B2 (en) | 2016-11-02 | 2023-09-01 | Engmab Sarl | A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma |
| JP2019535262A (ja) * | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| BR112019011277A2 (pt) | 2016-12-02 | 2019-10-22 | University Of Southern California | polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos. |
| CA3048648A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
| WO2018151836A1 (en) * | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| GB201709508D0 (en) * | 2017-06-15 | 2017-08-02 | Autolus Ltd | Chimeric antigen receptor |
| JP2020530993A (ja) * | 2017-08-02 | 2020-11-05 | オートラス リミテッド | キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| MX2020004568A (es) * | 2017-11-06 | 2020-10-05 | Juno Therapeutics Inc | Combinación de una terapia celular y un inhibidor de gamma secretasa. |
| CN109971715A (zh) * | 2017-12-28 | 2019-07-05 | 深圳华大生命科学研究院 | 一种扩增特异性car-t细胞的培养方法 |
| AU2019206573B2 (en) * | 2018-01-10 | 2024-06-06 | The General Hospital Corporation | Immune cells expressing a chimeric antigen receptor |
| CA3074526C (en) * | 2018-02-01 | 2021-08-03 | Nanjing Iaso Biotherapeutics Co., Ltd. | Chimeric antigen receptor (car) binding to bcma and application thereof |
| EP3768699B1 (en) * | 2018-03-23 | 2025-11-12 | Gavish-Galilee Bio Applications Ltd. | Genetically reprogrammed tregs expressing membrane-bound il-10 |
| GB201807693D0 (en) | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
| CN112566643A (zh) | 2018-06-12 | 2021-03-26 | 加利福尼亚大学董事会 | 用于治疗癌症的单链双特异性嵌合抗原受体 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| MX2021003636A (es) | 2018-09-27 | 2021-07-21 | Autolus Ltd | Receptor antigenico quimerico. |
| AU2019372331A1 (en) | 2018-11-01 | 2021-05-27 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| EP3873937A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| WO2020120982A2 (en) | 2018-12-14 | 2020-06-18 | Autolus Limited | Cell |
| GB201904160D0 (en) | 2019-03-26 | 2019-05-08 | Autolus Ltd | Cell |
| WO2020172643A2 (en) * | 2019-02-21 | 2020-08-27 | Luk John M | Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| CN113543792A (zh) | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| WO2020194306A1 (en) * | 2019-03-26 | 2020-10-01 | Gavish-Galilee Bio Applications Ltd. | Genetically reprogrammed tregs expressing cars |
| GB201904971D0 (en) | 2019-04-08 | 2019-05-22 | Autolus Ltd | Cell |
| GB201906202D0 (en) | 2019-05-02 | 2019-06-19 | Autolus Ltd | Cell |
| CN113784733B (zh) | 2019-05-07 | 2024-09-06 | 亘喜生物科技（上海）有限公司 | 靶向bcma的工程化免疫细胞及其用途 |
| JP7741732B2 (ja) | 2019-05-07 | 2025-09-18 | グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド | Ｂｃｍａを標的とする操作された免疫細胞及びその使用 |
| CU20210096A7 (es) | 2019-05-21 | 2022-06-06 | Novartis Ag | Moléculas de unión a cd19 |
| CN110592015A (zh) * | 2019-09-27 | 2019-12-20 | 中国科学院西双版纳热带植物园 | 一种诱导增强cik细胞的滇重楼多糖组合物及其应用 |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| KR20250047766A (ko) | 2022-08-05 | 2025-04-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Gprc5d 및 bcma에 특이적인 키메라 항원 수용체 |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| GB202403564D0 (en) | 2024-03-12 | 2024-04-24 | Autolus Ltd | Method |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2303615A1 (en) * | 1997-09-12 | 1999-03-18 | Jurg Tschopp | April- a novel protein with growth effects |
| UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| NZ521629A (en) * | 2000-04-27 | 2004-05-28 | Biogen Inc | TACI as an anti-tumor agent |
| CA2419661A1 (en) * | 2000-08-15 | 2002-03-07 | Guo-Liang Yu | Neutrokine-alpha and neutrokine-alpha splice variant |
| AU2002238052A1 (en) * | 2001-02-20 | 2002-09-04 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| SI1997512T1 (sl) * | 2002-04-09 | 2014-03-31 | Biogen Idec Ma Inc. | Postopki za zdravljenje stanj, povezanih s TWEAK-om |
| WO2004027026A2 (en) * | 2002-09-19 | 2004-04-01 | Biogen Idec Ma Inc. | Improved methods for preparing highly active april ligand polypeptides |
| CA2590461A1 (en) * | 2004-12-23 | 2006-06-29 | Laboratoires Serono S.A. | Bcma polypeptides and uses thereof |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| KR102086874B1 (ko) * | 2012-04-11 | 2020-03-10 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| CN103145849B (zh) * | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
| GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| ES2737690T3 (es) | 2014-02-27 | 2020-01-15 | Ucl Business Ltd | Variantes de APRIL |
| JP2019535262A (ja) | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| GB201709508D0 (en) | 2017-06-15 | 2017-08-02 | Autolus Ltd | Chimeric antigen receptor |
| AU2019206573B2 (en) * | 2018-01-10 | 2024-06-06 | The General Hospital Corporation | Immune cells expressing a chimeric antigen receptor |
-
2013
- 2013-10-10 GB GBGB1317929.6A patent/GB201317929D0/en not_active Ceased
-
2014
- 2014-10-10 CN CN201480055657.6A patent/CN105658671B/zh active Active
- 2014-10-10 MX MX2016004362A patent/MX2016004362A/es unknown
- 2014-10-10 SG SG11201602414SA patent/SG11201602414SA/en unknown
- 2014-10-10 EP EP14784368.4A patent/EP3055326B1/en active Active
- 2014-10-10 RU RU2019102382A patent/RU2019102382A/ru not_active Application Discontinuation
- 2014-10-10 KR KR1020167012121A patent/KR20160067177A/ko not_active Withdrawn
- 2014-10-10 RU RU2016117383A patent/RU2684713C2/ru not_active IP Right Cessation
- 2014-10-10 AU AU2014333564A patent/AU2014333564B2/en not_active Ceased
- 2014-10-10 BR BR112016007805A patent/BR112016007805A2/pt not_active Application Discontinuation
- 2014-10-10 JP JP2016521314A patent/JP6632073B2/ja active Active
- 2014-10-10 US US15/028,064 patent/US10160794B2/en active Active
- 2014-10-10 ES ES14784368T patent/ES2918626T3/es active Active
- 2014-10-10 CA CA2926560A patent/CA2926560A1/en not_active Abandoned
- 2014-10-10 WO PCT/GB2014/053058 patent/WO2015052538A1/en not_active Ceased
-
2016
- 2016-03-28 IL IL244784A patent/IL244784A0/en unknown
- 2016-03-30 CL CL2016000734A patent/CL2016000734A1/es unknown
-
2018
- 2018-10-17 US US16/162,747 patent/US10919951B2/en active Active
-
2019
- 2019-01-10 JP JP2019002499A patent/JP2019052190A/ja not_active Withdrawn
-
2020
- 2020-10-22 US US17/077,782 patent/US20210101959A1/en not_active Abandoned
-
2023
- 2023-05-22 US US18/321,400 patent/US20240076352A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016007805A2 (pt) | 2017-12-05 |
| EP3055326A1 (en) | 2016-08-17 |
| RU2016117383A (ru) | 2017-11-15 |
| JP2019052190A (ja) | 2019-04-04 |
| GB201317929D0 (en) | 2013-11-27 |
| CL2016000734A1 (es) | 2017-05-19 |
| IL244784A0 (en) | 2016-04-21 |
| US20160237139A1 (en) | 2016-08-18 |
| SG11201602414SA (en) | 2016-04-28 |
| EP3055326B1 (en) | 2022-04-20 |
| KR20160067177A (ko) | 2016-06-13 |
| US20190100571A1 (en) | 2019-04-04 |
| HK1222186A1 (en) | 2017-06-23 |
| MX2016004362A (es) | 2016-10-13 |
| CA2926560A1 (en) | 2015-04-16 |
| RU2684713C2 (ru) | 2019-04-11 |
| RU2019102382A (ru) | 2019-02-22 |
| US10919951B2 (en) | 2021-02-16 |
| RU2016117383A3 (OSRAM) | 2018-05-22 |
| US20240076352A1 (en) | 2024-03-07 |
| AU2014333564A1 (en) | 2016-04-28 |
| AU2014333564B2 (en) | 2018-09-27 |
| JP6632073B2 (ja) | 2020-01-15 |
| US10160794B2 (en) | 2018-12-25 |
| CN105658671B (zh) | 2021-08-27 |
| US20210101959A1 (en) | 2021-04-08 |
| JP2016538830A (ja) | 2016-12-15 |
| WO2015052538A1 (en) | 2015-04-16 |
| CN105658671A (zh) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2918626T3 (es) | Receptor antigénico quimérico. | |
| ES2737690T3 (es) | Variantes de APRIL | |
| CN105848673B (zh) | 细胞 | |
| ES3039696T3 (en) | Cell | |
| CN106573989A (zh) | 信号传导系统 | |
| CA3002774A1 (en) | Programmable universal cell receptors and methods of using the same | |
| HK1222186B (en) | Chimeric antigen receptor | |
| WO2025088214A1 (en) | Computationally designed binders for immune cell therapies | |
| HK1227893B (en) | April variants |